Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

Joshua F Zeidner; Flora Mazerolle; Jonathan Norton; Antoine Regnault; Fjoralba Kristo; Heather Romero; Robert J Fram; Douglas V Faller; Mehul Dalal; Lionel Ades; Mikkael A Sekeres

doi:10.3324/haematol.2022.281856

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

Haematologica. 2023 Apr 1;108(4):1196-1199. doi: 10.3324/haematol.2022.281856.

Affiliations

¹ University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC. [email protected].
² Modus Outcomes, a division of THREAD, Lyon.
³ Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA.
⁴ AP-HP, Hôpital Saint Louis, Paris, France; University of Paris, and INSERM U944, Paris.
⁵ Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Blood Transfusion
Humans
Myelodysplastic Syndromes* / therapy
Patient-Centered Care

Grants and funding

Funding: This work and the P-2001 study were funded by Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Ltd. Company.